1. Home
  2. RBBN vs RLMD Comparison

RBBN vs RLMD Comparison

Compare RBBN & RLMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Ribbon Communications Inc.

RBBN

Ribbon Communications Inc.

N/A

Current Price

$1.46

Market Cap

355.8M

Sector

Technology

ML Signal

N/A

Logo Relmada Therapeutics Inc.

RLMD

Relmada Therapeutics Inc.

N/A

Current Price

$4.26

Market Cap

348.8M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
RBBN
RLMD
Founded
1997
2004
Country
United States
United States
Employees
N/A
N/A
Industry
EDP Services
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
355.8M
348.8M
IPO Year
2017
2012

Fundamental Metrics

Financial Performance
Metric
RBBN
RLMD
Price
$1.46
$4.26
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
5
4
Target Price
$3.08
★ $10.75
AVG Volume (30 Days)
1.2M
★ 1.6M
Earning Date
10-27-2026
11-12-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 170.97
45.28
EPS
★ N/A
N/A
Revenue
N/A
★ $13,070.00
Revenue This Year
N/A
N/A
Revenue Next Year
$5.15
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
★ 154.83
52 Week Low
$1.28
$3.07
52 Week High
$3.41
$8.00

Technical Indicators

Market Signals
Indicator
RBBN
RLMD
Relative Strength Index (RSI) 45.40 59.22
Support Level $1.30 $4.19
Resistance Level $1.87 $4.53
Average True Range (ATR) 0.11 0.36
MACD 0.01 0.09
Stochastic Oscillator 31.17 66.78

Price Performance

Historical Comparison
RBBN
RLMD

About RBBN Ribbon Communications Inc.

Ribbon Communications Inc provides communications technology to service providers and enterprises, offering software and high-performance hardware products, network solutions, and services for secure data and voice communications, as well as high-bandwidth networking for residential and enterprise customers across industries such as finance, education, government, utilities, and transportation. It operates through two segments: Cloud and Edge, which generate maximum revenue and deliver software-centric, cloud-native solutions for VoIP, VoLTE, VoNR, and unified communications, and IP Optical Networks, which support growing telecommunications traffic from 5G, distributed cloud computing, and other applications. The Company generates the majority of its revenue from the United States.

About RLMD Relmada Therapeutics Inc.

Relmada Therapeutics Inc is a clinical-stage, publicly traded biotechnology company focused on the development of NDV-01 and sepranolone. NDV-01 is a novel, controlled-release intravesical formulation of gemcitabine and docetaxel. NDV-01 is currently in a Phase 2 clinical trial in Isreal to assess its safety and efficacy in patients with aggressive forms of non-muscle invasive bladder cancer (NMIBC). Sepranolone is a novel neurosteroid epimer of allopregnanolone. sepranolone is being developed for the potential treatment of Prader-Willi Syndrome, Tourette Syndrome, excessive tremor and other diseases related to excessive GABAergic activity.

Share on Social Networks: